Cardiol Therapeutics (CRDL) Common Equity (2020 - 2026)

Cardiol Therapeutics' Common Equity history runs 7 years deep, the most recent figure standing at $17.6 million for Q1 2026.

• Quarterly Common Equity rose 43.99% year-over-year to $17.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.6 million (up 43.99% YoY) and the FY2025 annual result came in at $12.8 million, down 27.58% from the prior year.
• Common Equity was $17.6 million for Q1 2026 at Cardiol Therapeutics, up from $12.8 million in the prior quarter.
• Across five years, Common Equity topped out at $54.6 million in Q1 2022 and bottomed at $6.9 million in Q3 2025.
• A 5-year average of $23.9 million and a median of $17.7 million in 2024 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity surged 94.72% — and 2024, when it plunged 70.6%.
• Cardiol Therapeutics' Common Equity stood at $38.5 million in 2022, then tumbled by 46.05% to $20.7 million in 2023, then retreated by 14.68% to $17.7 million in 2024, then dropped by 27.58% to $12.8 million in 2025, then soared by 37.67% to $17.6 million in 2026.
• Business Quant data shows CRDL's Common Equity at $17.6 million in Q1 2026, $12.8 million in Q4 2025, and $6.9 million in Q3 2025.